| Literature DB >> 31700814 |
Yalda Malekzadegan1, Mehrdad Halaji2,3, Meysam Hasannejad-Bibalan4, Saba Jalalifar2, Javad Fathi1, Hadi Sedigh Ebrahim-Saraie5.
Abstract
BACKGROUND: Clostridium difficile is the most common causes of hospital-acquired diarrhea affecting particularly hospitalized patients globally. This organism has re-emerged in recent years with significant morbidity and mortality. The present study aimed to estimate the burden of C. difficile infection (CDI) and to acquire information on the overall rates of community- and hospital-acquired CDI in western Asia.Entities:
Keywords: Clostridium difficile infection (CDI); Infection control; Meta-analysis; Western Asia
Year: 2019 PMID: 31700814 PMCID: PMC6825664
Source DB: PubMed Journal: Iran J Public Health ISSN: 2251-6085 Impact factor: 1.429
Fig. 1:Flow chart of the literature search strategy and study selection
Characteristics of studies included in the meta-analysis
| Sadeghifard | 2010 | 2002–2006 | Iran | Diarrheal stool | No limit | H | Cytotoxicity assay | 942 | 57 | - | 30/27 | ( |
| Nazemalhosseini-Mojarad | 2011 | UN | Iran | Diarrheal stool | No limit | H and OP | ELISA | 356 | 19 | - | 13/6 | ( |
| Nasri | 2012 | 2009–2010 | Iran | Diarrheal stool | No limit | H | ELISA | 162 | 36 | - | 24/12 | ( |
| Jalali | 2012 | 2010–2011 | Iran | Diarrheal stool | No limit | H | Molecular | 86 | 17 | 13/4 | 9/8 | ( |
| Goudarzi | 2013 | 2010–2011 | Iran | Diarrheal stool | No limit | H | Molecular | 350 | 75 | - | 39/36 | ( |
| Farshad | 2013 | 2012 | Iran | Nosocomial diarrhea | No limit | H | Cytotoxicity assay and ELISA | 122 | 9 | 9/- | 5/4 | ( |
| Azizi | 2013 | 2010 | Iran | Nosocomial diarrhea | No limit | H | Molecular | 98 | 15 | - | - | ( |
| Alinejad | 2015 | 2013–2014 | Iran | Nosocomial diarrhea | 6–60 months | H | ELISA | 38 | 8 | 8/- | 6/2 | ( |
| Rezazadeh Zarandi | 2017 | 2014–2015 | Iran | Diarrheal stool | No limit | H | Molecular and ELISA | 233 | 11 | - | - | ( |
| Azimirad | 2017 | 2011–2012 | Iran | Diarrheal stool | No limit | H | Molecular | 105 | 18 | - | 9/10 | ( |
| Sandokji | 2009 | 2007–2008 | Saudi Arabia | Diarrheal stool | >2 yr | H | ELISA | 258 | 56 | 56/- | - | ( |
| Al-Tawfiq | 2010 | 2007–2008 | Saudi Arabia | Diarrheal stool | No limit | H and OP | ELISA | 913 | 42 | 26/16 | 23/19 | ( |
| AL-Eidan | 2013 | 2011 | Saudi Arabia | Diarrheal stool | Adult | H | ELISA | 2927 | 171 | 98/73 | - | ( |
| Senok | 2017 | 2014–2015 | Saudi Arabia | Diarrheal stool | No limit | H and OP | Molecular | 210 | 31 | - | - | ( |
| Jamal | 2010 | 2003–2005 | Kuwait | Diarrheal stool | No limit | H and OP | ELISA | 697 | 73 | 56/17 | - | ( |
| Jamal | 2014 | 2012 | Kuwait | Diarrheal stool | >2 yr | OP | Molecular | 409 | 13 | -/13 | - | ( |
| Jamal | 2015 | 2011–2013 | Kuwait | Diarrheal stool | >2 yr | OP | ELISA | 2548 | 16 | -/16 | - | ( |
| Albert | 2016 | 2014–2015 | Kuwait | Diarrheal stool | No limit | H | Molecular | 109 | 3 | - | - | ( |
| Alrifai | 2009 | 2004–2005 | Iraq | Nosocomial diarrhea | 1–60 months | H | ELISA | 81 | 17 | - | ( | |
| Al-Thani | 2014 | 2011–2012 | Qatar | Diarrheal stool | >1 yr | H and OP | EIA and Molecular | 1,532 | 122 | 98/14 | 72/50 | ( |
Abbreviations: ELISA: enzyme-linked immunosorbent assay; EIA: Enzyme Immunoassay; HA: hospital-acquired; CA: community-acquired; M: male; F: female.
Fig. 2:Forest plot of the pooled prevalence of CDI in western Asia
Fig. 3:Funnel plot of meta-analysis on CDI in western Asia
Fig. 4:Forest plot of the pooled prevalence of community- or hospital-acquired
Fig. 5:Forest plot of the pooled prevalence of male and female patients with CDI
Fig. 6:Forest plot of subgroups analysis of the pooled prevalence of CDI between countries in western Asia